Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017

SAN DIEGO, Oct. 25, 2016 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its quarter ended September 30, 2016. Revenue for the quarter was $465.4 million, a 13 percent increase compared to the same period of the prior year. Excluding the contribution from the Brightree acquisition, revenue for the quarter was $432.4 million, a 5 percent increase.    

"We had a solid start to our fiscal year with 13 percent constant currency revenue growth led by our Brightree software offerings and global device sales," said Mick Farrell, ResMed's chief executive officer. "We continue to demonstrate the value... More

Results from World's Largest Study on Sleep Apnea and Digital Connected Care

LOS ANGELES, Oct. 25, 2016 /PRNewswire/ -- In a new research study being presented tomorrow at the CHEST 2016 annual meeting, ResMed (NYSE: RMD) will share evidence that people who use a self-management app when treating their sleep apnea with positive airway pressure (PAP) are significantly more likely to stick with their therapy.

The observational study included more than 128,000 people with sleep... More

How Technology is Tackling the World's Greatest Healthcare Challenges in the Era of Personalized Medicine, at the Digital Health Summit at CES 2017

NEW YORK, Oct. 24, 2016 /PRNewswire/ -- The digital health market is expected to reach $233 billion by 2020 with the fight against disease getting personal.  Medicine can be tailored to fit an individual's DNA, mobile health innovations are letting patients take more control and contribute to their outcomes and new tools are analyzing massive amounts of cloud data and creating new strategies to combat some of medicine's most vexing problems. ... More